8-K current report · filed Oct 27, 2026

Spero Therapeutics Inc (SPRO) 8-K Current Report: October 27, 2026

Item 5.02SPRO overview

Short answer

Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics.

Spero Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics
  • Transition consulting expected through approximately February 28, 2027, terminable on 15 days’ notice
  • Hourly consulting compensation during transition, with no rate disclosed
  • Leadership succession and operational continuity become near-term investor considerations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spero Therapeutics Inc 8-K filings

Get the next SPRO 8-K as it lands

Follow SPRO for push alerts, or ask the research agent what this filing means.